Thursday, June 23, 2016
- 12:00pm-1:30pm
-
Duodenal levodopa infusion: Safety and efficacy in a 6 years outpatient follow-up
Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2
- 12:00pm-1:30pm
-
Duodopa treatment experience in Oradea
Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2
- 12:00pm-1:30pm
-
Duration of levodopa treatment and prevalence of osteoporosis in patients with Parkinson’s disease
Other · Exhibit Hall located in Hall B, Level 2
- 12:00pm-1:30pm
-
Dynamic prediction for multiple repeated measures and event time data: An application to Parkinson’s disease
Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2
- 12:00pm-1:30pm
-
Dystonia after peripheral nerve injury in DYT1 transgenic rats
Dystonia · Exhibit Hall located in Hall B, Level 2
- 12:00pm-1:30pm
-
Dystonia-deafness syndrome caused by beta -actin gene mutation and the effect of pallidal deep brain stimulation
Dystonia · Exhibit Hall located in Hall B, Level 2
- 12:00pm-1:30pm
-
Dystonia, myoclonus, and tremor without epilepsy associated with a mutation in STXBP1
Pediatric movement disorder · Exhibit Hall located in Hall B, Level 2
- 12:00pm-1:30pm
-
Dystonia, tremor, and dystonic tremor
- 12:00pm-1:30pm
-
DYT16/PRKRA founder mutation causes childhood-onset generalized dystonia in a family from southern Italy
- 12:00pm-1:30pm
-
DYT2 dystonia – Too rare to be found?
Dystonia · Exhibit Hall located in Hall B, Level 2
- «Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 53
- Next Page»